Visivite launches gentle macular health formula, AREDS2 Silver

NewsGuard 100/100 Score

VisiVite®, a world leader in eye vitamins, today announced its launch of a gentle new macular health formula: AREDS2 Silver®. Based on the National Eye Institute's Age-Related Eye Disease Studies (AREDS and AREDS2), AREDS2 Silver supplies antioxidants for macular health without the high levels of zinc that may cause issues in those with zinc sensitivities and allergies.

The first AREDS study found that an antioxidant supplement of beta carotene, vitamin C, vitamin E and zinc appeared to reduce the risk of age-related macular changes. AREDS2, its follow-up study, revealed that plant-based antioxidants lutein and zeaxanthin could be substituted for beta-carotene, which is associated with health risks in smokers and absorption challenges in others. AREDS2 also found that there were no significant differences between low dose zinc and high dose zinc in the formula's success. 

VisiVite's AREDS2 Silver is calibrated to match these findings, supplying a gentle 40 mg zinc serving that may be preferable for those who have zinc sensitivities. AREDS2 Silver also features:

  • FloraGLO® Lutein (10 mg): A macular antioxidant sourced from marigold flowers
  • OmniXan® Zeaxanthin (2 mg): Prized paprika-sourced broad-spectrum antioxidants
  • Vitamin C (500 mg) & Vitamin E (400 IU): Bioavailable & natural antioxidants

"It is our mission at VisiVite to provide eye health supplements that are constantly evolving and updating to match the latest scientific research," says Dr. Paul Krawitz, acclaimed Ophthalmologist, Vitamin Science, Inc. C.E.O., and VisiVite product formulator. "With our new AREDS2 Silver formula, we are leveraging the newest findings that suggest lower dose zinc works just as well as higher doses. AREDS2 Silver enables zinc-sensitive populations to nourish their eyes with an evidence-backed antioxidant complex that is both well-tolerated and highly effective in promoting macular health."

Source: Vitamin Science Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers aim to use AI for early screening and prognosis of Dry Eye Disease